Research
ACAAI: Considerable delay seen from Rx to approval for children's biologics
The Brief
- A study presented at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) found a considerable delay between prescribing a biologic therapy and final approval for pediatric patients.
- Almost 40% of prescriptions that require prior authorization (PA) are denied, according to the study.
Why it matters
Children who need biologic therapy may face long waits and frequent denials before treatment starts, which can delay care for their conditions.
Who’s affected
- families of children prescribed biologic therapies
- clinicians who prescribe biologics to pediatric patients
- #pediatrics
- #biologics
- #prior authorization
- #allergy
- #health policy
There is a considerable delay from prescription of biologic therapy to final approval for pediatric patients, and almost 40% of prescriptions requiring a prior authorization (PA) are denied, according to a study presented at the annual meeting of the American College of Allergy…